Spring Issue of GIST Cancer Journal has Arrived
The Life Raft Group is pleased to announce the release of the ninth issue of The GIST Cancer Journal, the official journal of the Life Raft Group. The journal is intended to serve as [...]
GIST Cancer Journal Winter 2015 Issue
The Life Raft Group is pleased to announce the release of the eighth issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely [...]
Blueprint Medicines Presents Preclinical Data on BLU-285
Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]
New research supports role for crenolanib
A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent [...]
D842V Gets Its Moment in the Spotlight
The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.
New Treatments of D842V Mutations
UPDATE - January 6th, 2011 by Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled [...]
References – PDGFRA and D842V
1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. [...]
KIT and PDGFRA Mutations in GIST: A to Z
This is part one of a two-part series on “KIT and PDGFRA kinase mutations in GIST: from A to Z”. In this newsletter, Dr. Heinrich will provide a background on the role of kinase mutations in GIST, focusing largely on the biological and clinical implications of these mutations. In part two (which will be featured in the July 2007 edition of the newsletter, following the special “Five-year anniversary” edition),
PKC412 inhibits D842 mutation
March, 2005 - Novartis drug can inhibit secondary KIT mutations By Jerry Call Life Raft Group science coordinator Recently reported research further defines the mechanisms of resistance that GIST tumors use to thwart Gleevec. [...]